Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIFT-001: HIM Subtyping-Guided Treatment in Advanced Triple-Negative Breast Cancer
NCT06849492Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, paclitaxel, sacituzumab tirumotecan and lenvatinib in triple-negative breast cancer (TNBC) (3 cohorts), sponsored by Fudan University. Primary endpoint: Objective Response Rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelsacituzumab tirumotecanlenvatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06849492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849492.